echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > For use in Fahrenheit macroglobulinemia, Baekje Zebutinib is recommended by NICE in the UK

    For use in Fahrenheit macroglobulinemia, Baekje Zebutinib is recommended by NICE in the UK

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Yesterday, Baekje announced that the European Commissioner's European Medicines Agency (EMA) Committee on Pharmaceuticals for Human Use (CHMP) has issued its positive opinion recommending Beyondt ® (zebutinib) for marketing authorization, recommending approval ® for the treatment of adults with
    marginal zone lymphoma (MZL) who have previously undergone at least one anti-CD20 therapy.


    Approved ® for the treatment of adults with
    marginal zone lymphoma (MZL) who have previously received at least one anti-CD20 therapy.


    Adult patients with
    Fahrenheit macroglobulinemia (WM).


    NICE's decision marks the ® first and only conventional drug
    recommended for WM in England and Wales.


    WM is a rare B-cell lymphoma that makes up only 2%
    of non-Hodgkin lymphoma patient population.


    Dr Shirley D'Sa, Consultant and Clinical Leader of the Hematology Department at the WM and Related Diseases Centre at University College London, said: "Beaux-Centro ® is a highly selective BTK inhibitor
    .


    In this assessment, NICE believes that Baiyueze ® can be seen as a "significant advance"
    in WM treatment.


    Dr Robert Mulrooney, General Manager of BeiGene, UK and Ireland, said: "I am delighted that NICE has listed NICE ® as an important treatment option for WM patients in England and Wales who meet the treatment standards, which will make WM patients in these regions the first people
    in Europe to be able to use Beaux.


    About Fahrenheit macroglobulinemia

    About Fahrenheit macroglobulinemia

    Fahrenheit macroglobulinemia (WM) is a rare B-cell lymphoma that accounts for only 2%
    of non-Hodgkin lymphoma patients.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.